56980-14-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxy-2-(4-MethoxyphenylaMino)benzoic acid is used as an intermediate in the synthesis of more complex pharmaceutical compounds. Its unique structure allows for the creation of a variety of biologically active molecules with potential therapeutic applications.
Used in Chemical Industry:
5-Methoxy-2-(4-MethoxyphenylaMino)benzoic acid is used as a building block for the construction of photoswitchable macrocycles incorporating acridane moieties. These macrocycles have potential applications in various fields, including materials science and molecular electronics, due to their ability to undergo reversible photochemical reactions.

InChI:InChI=1/C15H15NO4/c1-19-11-5-3-10(4-6-11)16-14-8-7-12(20-2)9-13(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)

Upstream product

• 104-94-9 4-methoxy-aniline 
• 22921-68-2 2-bromo-5-methoxy-benzoic acid 

Downstream Products

• 6526-93-8 2,7-dimethoxy-9-phenoxy-acridine 
• 6526-92-7 2,7-Dimethoxy-9-chloroacridine 

Relevant academic research and scientific papers

Antitumor compound, synthesis method and applications thereof

The invention belongs to the field of medicinal chemistry, and particularly relates to an antitumor compound, a synthesis method and applications thereof, wherein the compound has a structure represented by a general formula I or a general formula II, and

Acridinium-Based Photocatalysts: A Sustainable Option in Photoredox Catalysis

The emergence of visible light photoredox catalysis has enabled the productive use of lower energy radiation, leading to highly selective reaction platforms. Polypyridyl complexes of iridium and ruthenium have served as popular photocatalysts in recent ye

ACRIDINES AS INHIBITORS OF HASPIN AND DYRK KINASES

The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DY

Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors

Haspin is a serine/threonine kinase required for completion of normal mitosis that is highly expressed during cell proliferation, including in a number of neoplasms. Consequently, it has emerged as a potential therapeutic target in oncology. A high throughput screen of approximately 140,000 compounds identified an acridine analog as a potent haspin kinase inhibitor. Profiling against a panel of 270 kinases revealed that the compound also exhibited potent inhibitory activity for DYRK2, another serine/threonine kinase. An optimization study of the acridine series revealed that the structure-activity relationship (SAR) of the acridine series for haspin and DYRK2 inhibition had many similarities. However, several structural differences were noted that allowed generation of a potent haspin kinase inhibitor (33, IC50 50 400 nM) with a 5.4-fold selectivity over haspin was also identified.

Photoswitchable macrocycles incorporating acridane moieties

Novel crown ethers incorporating one to three 9-phenyl-acridinium units were synthesized in moderate yields. The acridinium units within the macrocycles were converted into the photoactive N-methyl-9-methoxy-9-phenyl-9,10- dihydroacridine (N-methyl-9-methoxy-9-phenylacridane) units. Georg Thieme Verlag Stuttgart.

Potential anticancer agents derived from acridine

The compounds of the subject invention can be represented as follows: STR1 wherein each of R1, R2, R3, R4, are the same or different and are hydrogen (H), or a lower alkyl group of from about 1-4 carbon atoms, o